Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix to Distribute Almac's Xcel Array for Biomarker Discovery

Premium

By Justin Petrone

Affymetrix will sell Almac Diagnostics' Xcel array for biomarker discovery and development to its clients worldwide, the firms said last week.

Craigavon, UK-based Almac launched the Xcel array via a service in 2010 (BAN 6/8/2010). Affy manufactures the chip, which is optimized for use with formalin-fixed, paraffin-embedded tissue samples. The array contains 97,000 transcripts and was designed for use in studies where cross-disease compatibility is important. Almac also offers a menu of disease-specific arrays for profiling expression in specific cancers, including colorectal, lung, ovarian, and prostate cancers.

Austin Tanney, Almac's scientific liaison officer, told BioArray News that Almac has seen "significant demand and interest" in the array since it was launched, and that the firm has supported that demand via a service model, but that it was time to make the chip available in a kit format.

"With the increasing demand and interest in Xcel for a diverse range of applications it has become apparent that there is a real opportunity to open up access to the platform to wider distribution and Affymetrix [was] the best partner to do this with," Tanney said.

Kevin Cannon, expression business lead at Affy, said in a statement that the Xcel array is "ideal" for gene-expression profiling from FFPE tissues, and a "significant technology advancement."

Further details of the agreement were not disclosed.


Have topics you'd like to see covered in BioArray News? Contact the editor at jpetrone [at] genomeweb [.]com.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more